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Small bowel adenocarcinoma is a rare but well-known complication of Crohn’s disease. The diagnosis of small bowel
adenocarcinoma remains difficult since its presentation is highly variable and mimics active or obstructive Crohn’s disease. The
diagnosis is often delayed and typically detected only at surgery in an advanced stage with a poor prognosis. We report a case of
metastatic ileal adenocarcinoma in a patient with Crohn’s disease with prolonged survival. Our case describes serial promising
treatment options of these advanced malignancies and raises a possible role for checkpoint immunotherapy.
1. Introduction
Small bowel adenocarcinoma (SBA) is a rare but well-known
complication of Crohn’s disease (CD) that was first described
by Ginzburg et al. [1]. As per Surveillance, Epidemiology, and
End Results (SEER) in 2018, it is expected that there will be
10,470 new cases of small bowel cancer [2]. The diagnosis
of SBA remains difficult since its clinical presentation is
highly variable and it may simulate active or obstructive
CD [3, 4]. The diagnosis is often delayed and is typically
detected at surgery in an advanced stage with a poor progno-
sis [5]. There is no clear guideline available for an optimal
treatment regimen for either adjuvant chemotherapy or
CD-associated metastatic SBA. The standard approach, emu-
lating treatment regimens used for colorectal cancer, has had
limited palliative success [6]. There is an essential need for
the evaluation of novel strategies to treat these rare malignan-
cies. We report a case of metastatic SBA in a patient with CD
with prolonged survival.
2. Case Report
A 31-year-old Persian male with a family history positive for
colon cancer in his grandfather had CD diagnosed since
childhood. He underwent ileocolic resection for obstructive
disease in 1996. He was maintained on mercaptopurine
(6-MP) prophylaxis and did well until 2007 with occasional
bouts of cramping and obstructive symptoms. He had a colo-
noscopy done in December 2007 that showed normal termi-
nal ileum and colon. In February 2008, a computerized
tomography (CT) scan of the abdomen showed two abnor-
mal areas of stricture proximal and mid-ileum.
In June 2008, CT scan of the abdomen showed two areas
of bowel dilation along with two hypodense liver lesions. In
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September 2008, the patient underwent resection of strictures
and was found to have SBA as well as liver metastases.
No lymph node (LN) dissection was performed because the
diagnosis of cancer was not confirmed at the time of surgery.
Histopathology showed poorly differentiated mucinous
adenocarcinoma and underlying CD (Figure 1). The tumor
infiltrated into the mesenteric fat and metastasized to the
liver and adjacent LNs. It was classified as T4N1M1.
In October 2008, positron emission tomography (PET)
scan showed nine metastatic liver lesions without other
intra-abdominal uptake. He was given FOLFOX (leucovorin
calcium, fluorouracil, and oxaliplatin) for a total of 12 cycles
until chronic toxicity and weakness, due to poor nutrition,
severe weight loss, poor fistula control, severe neuropathy,
and moderate leucopenia and thrombocytopenia, limited
further treatment (Table 1). A repeat PET scan, done in
December 2008, showed interval resolution of the majority
of the liver mets except 2 enhancing lesions on the left liver
lobe and the stable appearance of small bowel thickening.
He underwent left liver lobectomy (segment 7) for the met-
astatic tumor in January 2009. He then had four additional
cycles of FOLFOX. FOLFOX was discontinued when he
developed severe weight loss, worsening severe neuropathy,
and chronic moderate granulocytopenia and thrombocyto-
penia resulting discontinuation of standard chemotherapy.
In December 2011, imaging patient was noted to have
enlarged LNs in the small bowel mesentery confirming
metastatic SBA. In April 2012, he was hospitalized with
abdominal cramping, distention, and hematochezia in the
setting of metastatic SBA. He underwent resection of the
large mesenteric mass of matted LNs resulting stricture
proximal to the previous ileocolic anastomosis and below
a prior jejunojejunostomy.
The patient was considered to be refractory due to wide-
spread disease progression to the peritoneal LNs, liver, and
lung, and his condition was unfit for standard treatments
due to severe weight loss, fistulae, neuropathy, and chronic
poor marrow reserve. Treatment began with half the stan-
dard dosage of all drugs (FOLFOX) with added gemcitabine
and as tolerated irinotecan (GFLIO) and nutritional support.
Follow-up positron emission tomography (PET) scan in
May 2015 showed no hypermetabolic activity with normal
tumor markers. During this time, the patient continued with
a fistulizing CD with infection, obstruction, and dehydration
requiring hospitalization and mesenchymal stromal cell
(MSC) infusion in December 2013 for the fistulizing CD.
CT scan in May 2014 and September 2015 revealed stable
disease without evidence of recurrence. PET scan done in
November 2015 showed the progression of the tumor.
Further treatment that began with Cetuximab along
with gemcitabine, 5-fluorouracil, irinotecan, leucovorin,
and oxaliplatin (GFLIO) produced a period of relatively sta-
ble disease with improved tumor markers, improved area of
stable disease by RECIST criteria.
In May 2016, surveillance imaging revealed the patient
had increased pulmonary nodules and metastasis to the
thoracic spine (T6-7). The patient underwent T6-7 lami-
nectomy and resection of the extradural tumor in February
2017 due to the threat posed by symptomatic bony metas-
tasis. Trastuzumab was added as the tumor was human
epidermal growth factor receptor 2-positive (HER-2/neu
amplified FISH 2.42). This produced regression of pulmo-
nary metastatic disease and a fall in CEA. The bony disease
became stable and was technically unevaluable. In March
2018, the patient was admitted to the hospital again with gas-
trointestinal (GI) bleeding from a Crohn’s related enterocu-
taneous fistula. He was found to have a recurrence of tumor
at the enterocutaneous fistula site with GI bleeding from peri-
stomal varices due to portal hypertension. His condition was
deemed nonsurgical. The patient was hospitalized again
in June 2018 and unfortunately succumbed to metastatic
disease. A detailed treatment course with the outcome is
summarized in Table 1.
3. Discussion
Small bowel adenocarcinoma (SBA) is a rare but well-known
complication of CD [7]. The cumulative risk of SBA in CD is
reported as 2.2% in 25 years of CD [4]. Bojesen et al. [8]
showed a standardized incidence ratio of developing SBA in
patients with CD to be 14.38 (95% confidence interval 8.78-
22.20) compared to the general population. The study
showed the absolute risk of SBA in patients with CD to be
9 per 100,000/year. In addition, the majority of the patients
(57%) with CD-associated SBA had moderate to severe dis-
ease with small bowel and upper gastrointestinal tract
involvement [8]. The diagnosis of SBA remains challenging
due to the nonspecific presentation which can mimic active
or obstructive CD [3, 4]. Imaging studies may be confused
with other complications of CD such as an abscess, a stric-
ture, or an inflammatory mass [4]. There are no specific
guidelines for SBA screening in CD patients, and thus, it is
typically detected at an advanced stage with poor prognosis
[3, 7]. At best, a two-year survival rate for CD-associated
SBA was 27% [9].
The treatment options for CD-associated metastatic SBA
are limited, and the evidence for the routine use of adjuvant
chemotherapy is still lacking. The general approach has been
to imitate the treatment regimens used for colorectal cancer.
There is evidence of beneficial effects regarding response and
survival using 5-FU in combination with platinum agents
and retrospective studies describing the use of irinotecan
Figure 1: Histologic section from tumor mass shows normal small
intestinal mucosa (blue arrowheads) and adjacent invasive
adenocarcinoma (black arrows).
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±5-FU [10, 11]. The role of active targeted therapies with
antiepidermal growth factor receptor (EGFR) and vascular
endothelial growth factor (VEGF) receptor therapies has
not been established [11]. Tsang et al. described a case of
advanced SBA treated with bevacizumab with gemcitabine
and oxaliplatin [12]. Research with basket protocols suggests
a general role for Trastuzumab as a treatment for HER2 pos-
itive GI cancers [13].
There is no clear guideline for an optimal treatment reg-
imen with primary chemotherapy for patients with advanced
SBA. Prior retrospective studies reported no significant sur-
vival benefit for patients who received primary chemother-
apy after resection of their primary tumors [5, 14, 15].
However, a retrospective study demonstrated that the use
of adjuvant chemotherapy for patients with resected SBA
was associated with increased disease-free survival [14]. The
feasibility and efficacy of gemcitabine, 5-fluorouracil, irinote-
can, leucovorin, and oxaliplatin (GFLIO) have been demon-
strated in patients with metastatic pancreatic cancer. The
rationale for the use of GFLIO in the patient population
was designed to approximate sequence-dependent synergis-
tic effects while minimizing the sequence-dependent toxic
effects among the four drugs. The GFLIO regimen allows
for the simultaneous administration of four drugs, safely, at
half their standard dosages. These drugs produce six syner-
gistic drug pairs. The combination and several of the drug
pairs have reversed drug resistance of many gastrointestinal,
gynecological, and genitourinary adenocarcinoma. The regi-
men was thought to reverse or delay the resistance of stan-
dard treatment when used in combination [16]. Schrock
et al. studied the large-scale genomic profiling of SBA and
comparison with colorectal cancer (CRC) and gastric carci-
noma (GC) [17]. The distribution of biomarkers favors fur-
ther testing of both gemcitabine and irinotecan [18].
There is an essential need for novel strategies to treat
these rare malignancies. Salem et al. [18] compared molec-
ular variations between SBA, right-sided colon cancers,
and gastroesophageal cancers and showed that frequently
mutated genes in SBA were TP53 (51%), KRAS (49%), APC,
SMAD4, PIK3CA, BRAF, CTNNB1, ATM, ERBB2, and
BRCA2. The study demonstrated that though SBA has some
molecular features in common with CRC and GC, it indeed
represents a unique genomic entity. In addition, immunohis-
tochemistry (IHC) evaluation of ~531 SBA patients showed
several biomarkers that include low RRM1 (80%), high
TOPO1 (41%), low TUBB3 (64%), low ERCC1 (76%),
and low TS (59%) had a favorable role for chemotherapy
drugs with gemcitabine, irinotecan, taxanes, oxaliplatin,
and fluorouracil (5-FU), respectively [18]. In our patient,
GFLIO chemotherapy was started prior to obtaining these
proteomic markers.
4. Conclusion
We report a case of metastatic SBA in a patient with CD with
prolonged survival of more than nine years on treatment
with chemotherapy. Our case of prolonged survival and
review of the GFLIO experience also found a ten-year
disease-free survivor following “adjuvant” or what had been
intended as palliative GFLIO therapy. This patient initially
had residual lymph node and margin positive SBCA [10].
These few long survivors suggest a possible role for check-
point immunotherapy. In addition, immunotherapy in
expert hands is no longer contraindicated for CD. Also,
when there is a rare neoplastic disease with long survivor-
ship, the chemical profile of these survivors warrants iden-
tification. The feasibility of (further) treatment of fragile
and resistant patients (with moderate dosages of combina-
tion chemotherapy and guidance provided by biomarker
assays) is noteworthy.
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